Logo

Publikacije (33334)

Nazad
Leandra Ziad A Zargar Abdul Niveen M Benjamin Cecilia Robe Abarca-Gómez Abdeen Hamid Abu-Rmeileh Acosta-Cazar, Leandra Abarca-Gómez, Z. Abdeen, Zargar Abdul Hamid, Niveen M. E. Abu-Rmeileh, Benjamín Acosta-Cázares, Cecilia S Acuin, R. Adams et al.

Bin Zhou, Yuan Lu, Kaveh Hajifathalian, J. Bentham, M. Cesare, G. Danaei, Honor Bixby, Melanie J. Cowan et al.

P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. Rajkumar, G. Srkalović et al.

BACKGROUND Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity. METHODS In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently. Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles (24 weeks). In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen. The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. RESULTS Of 193 patients who could be evaluated, 92 percent had been treated with three or more of the major classes of agents for myeloma, and in 91 percent, the myeloma was refractory to the therapy received most recently. The rate of response to bortezomib was 35 percent, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation. The median overall survival was 16 months, with a median duration of response of 12 months. Grade 3 adverse events included thrombocytopenia (in 28 percent of patients), fatigue (in 12 percent), peripheral neuropathy (in 12 percent), and neutropenia (in 11 percent). Grade 4 events occurred in 14 percent of patients. CONCLUSIONS Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

S. de Sanjosé, Wim Quint, L. Alemany, D. Geraets, J. Klaustermeier, B. Lloveras, S. Tous, A. Félix et al.

Bin Zhou, J. Bentham, M. Cesare, Honor Bixby, G. Danaei, Melanie J. Cowan, C. Paciorek, Gitanjali M Singh et al.

M. Jamal-Hanjani, G. Wilson, N. Mcgranahan, Nicolai J. Birkbak, T. Watkins, S. Veeriah, S. Shafi, Diana H. Johnson et al.

BACKGROUND Among patients with non‐small‐cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of driver events and evolutionary processes in early‐stage NSCLC. METHODS In this prospective cohort study, we performed multiregion whole‐exome sequencing on 100 early‐stage NSCLC tumors that had been resected before systemic therapy. We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between intratumor heterogeneity and recurrence‐free survival. RESULTS We observed widespread intratumor heterogeneity for both somatic copy‐number alterations and mutations. Driver mutations in EGFR, MET, BRAF, and TP53 were almost always clonal. However, heterogeneous driver alterations that occurred later in evolution were found in more than 75% of the tumors and were common in PIK3CA and NF1 and in genes that are involved in chromatin modification and DNA damage response and repair. Genome doubling and ongoing dynamic chromosomal instability were associated with intratumor heterogeneity and resulted in parallel evolution of driver somatic copy‐number alterations, including amplifications in CDK4, FOXA1, and BCL11A. Elevated copy‐number heterogeneity was associated with an increased risk of recurrence or death (hazard ratio, 4.9; P=4.4×10‐4), which remained significant in multivariate analysis. CONCLUSIONS Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor. (Funded by Cancer Research UK and others; TRACERx ClinicalTrials.gov number, NCT01888601.)

T. Sekine, André Perez-Potti, Olga Rivera-Ballesteros, K. Strålin, J. Gorin, Annika Olsson, Sian Llewellyn-Lacey, Habiba Kamal et al.

J. George, Jing S. Lim, S. Jang, Yupeng Cun, Luka Ozretić, G. Kong, F. Leenders, Xin Lu et al.

Nina Popović

Nerazvijena svijest o utjecaju ljudskih aktivnosti na stanje okolisa i porast populacije rezultiralo je problemom zagađenosti otpadnim tvarima i potrosnjom prirodnih resursa svjetski sirokih razmjera. Trenutno stanje utjecaja na okolis zahtijeva primjenu novih tehnologija u svrhu unapređenja održivog razvoja. Upravo zeleno inženjerstvo ima za cilj razvoj i primjenu tehnoloski i ekonomski održivih proizvoda, procesa i sustava u svrhu zastite ljudskog zdravlja i biosfere. Jedno od podrucja zelenog inženjerstva u nastajanju je biomimikrija. Biomimikrija je inovativna metoda tehnoloskog oponasanja prirodnih procesa, oblika i drugih rjesenja, koji su dokazali svoju dugotrajnu održivost i ucinkovitost kroz 3, 8 milijardi godina evolucijskog razvoja. Prema teoriji koju je objavila J. Benyus, priroda sadrži brojna rjesenja koja inženjeri mogu oponasati i primijeniti, a potrebno se voditi slijedecim pravilima: priroda kao model, priroda kao standard i priroda kao mentor. Ovim radom opisan je pregled najznacajnijih tehnoloskih rjesenja inspiriranih živim organizmima. Biomimikrija je kao disciplina, gledano na okolis, ekonomsku isplativost i drustvenu korisnost, možda najbolja strategija za opstanak covjecanstva te najbolji put prema održivoj buducnosti. Buduci da je problem odnosa prirode i covjeka jedan od znacajnijih problema u bioetici, cini se opravdanim promotriti i probleme biomimikrije i u bioetickom kontekstu.

R. Sandler, J. Everhart, M. Donowitz, Elizabeth Adams, K. Cronin, C. Goodman, E. Gemmen, Shefali Shah et al.

BACKGROUND & AIMS Gastrointestinal (GI) and liver diseases inflict a heavy economic burden. Although the burden is considerable, current and accessible information on the prevalence, morbidity, and cost is sparse. This study was undertaken to estimate the economic burden of GI and liver disease in the United States for use by policy makers, health care providers, and the public. METHODS Data were extracted from a number of publicly available and proprietary national databases to determine the prevalence, direct costs, and indirect costs for 17 selected GI and liver diseases. Indirect cost calculations were purposefully very conservative. These costs were compared with National Institutes of Health (NIH) research expenditures for selected GI and liver diseases. RESULTS The most prevalent diseases were non-food-borne gastroenteritis (135 million cases/year), food-borne illness (76 million), gastroesophageal reflux disease (GERD; 19 million), and irritable bowel syndrome (IBS; 15 million). The disease with the highest annual direct costs in the United States was GERD ($9.3 billion), followed by gallbladder disease ($5.8 billion), colorectal cancer ($4.8 billion), and peptic ulcer disease ($3.1 billion). The estimated direct costs for these 17 diseases in 1998 dollars were $36.0 billion, with estimated indirect costs of $22.8 billion. The estimated direct costs for all digestive diseases were $85.5 billion. Total NIH research expenditures were $676 million in 2000. CONCLUSIONS GI and liver diseases exact heavy economic and social costs in the United States. Understanding the prevalence and costs of these diseases is important to help set priorities to reduce the burden of illness.

P. Riederer, E. Sofić, W. Rausch, B. Schmidt, G. Reynolds, K. Jellinger, M. Youdim

Abstract: The regional distributions of iron, copper, zinc, magnesium, and calcium in parkinsonian brains were compared with those of matched controls. In mild Parkinson's disease (PD), there were no significant differences in the content of total iron between the two groups, whereas there was a significant increase in total iron and iron (III) in substantia nigra of severely affected patients. Although marked regional distributions of iron, magnesium, and calcium were present, there were no changes in magnesium, calcium, and copper in various brain areas of PD. The most notable finding was a shift in the iron (II)/iron (III) ratio in favor of iron (III) in substantia nigra and a significant increase in the iron (III)‐binding protein, ferritin. A significantly lower glutathione content was present in pooled samples of putamen, globus pallidus, substantia nigra, nucleus basalis of Meynert, amygdaloid nucleus, and frontal cortex of PD brains with severe damage to substantia nigra, whereas no significant changes were observed in clinicopathologically mild forms of PD. In all these regions, except the amygdaloid nucleus, ascorbic acid was not decreased. Reduced glutathione and the shift of the iron (II)/iron (III) ratio in favor of iron (III) suggest that these changes might contribute to pathophysiological processes underlying PD.

A. Zhernakova, A. Kurilshikov, M. Bonder, E. Tigchelaar, M. Schirmer, T. Vatanen, Z. Mujagic, A. V. Vila et al.

“Normal” for the gut microbiota For the benefit of future clinical studies, it is critical to establish what constitutes a “normal” gut microbiome, if it exists at all. Through fecal samples and questionnaires, Falony et al. and Zhernakova et al. targeted general populations in Belgium and the Netherlands, respectively. Gut microbiota composition correlated with a range of factors including diet, use of medication, red blood cell counts, fecal chromogranin A, and stool consistency. The data give some hints for possible biomarkers of normal gut communities. Science, this issue pp. 560 and 565 Two large-scale studies in Western Europe establish environment-diet-microbe-host interactions. Deep sequencing of the gut microbiomes of 1135 participants from a Dutch population-based cohort shows relations between the microbiome and 126 exogenous and intrinsic host factors, including 31 intrinsic factors, 12 diseases, 19 drug groups, 4 smoking categories, and 60 dietary factors. These factors collectively explain 18.7% of the variation seen in the interindividual distance of microbial composition. We could associate 110 factors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocrine cells, was exclusively associated with 61 microbial species whose abundance collectively accounted for 53% of microbial composition. Low CgA concentrations were seen in individuals with a more diverse microbiome. These results are an important step toward a better understanding of environment-diet-microbe-host interactions.

G. Cao, E. Sofić, R. Prior

Previously, some fruits were shown to contain high antioxidant activities. In this paper, we report the antioxidant activities of 22 common vegetables, one green tea, and one black tea measured using the automated oxygen radical absorbance capacity assay with three different reactive species:  a peroxyl radical generator, a hydroxyl radical generator, and Cu2+, a transition metal. Based on the fresh weight of the vegetable, garlic had the highest antioxidant activity (μmol of Trolox equiv/g) against peroxyl radicals (19.4) followed by kale (17.7), spinach (12.6), Brussels sprouts, alfalfa sprouts, broccoli flowers, beets, red bell pepper, onion, corn, eggplant (9.8−3.9), cauliflower, potato, sweet potato, cabbage, leaf lettuce, string bean, carrot, yellow squash, iceberg lettuce, celery, and cucumber (3.8−0.5); kale had the highest antioxidant activity against hydroxyl radicals followed by Brussels sprouts, alfalfa sprouts, beets, spinach, broccoli flowers, and the others. The green and black teas had muc...

Nema pronađenih rezultata, molimo da izmjenite uslove pretrage i pokušate ponovo!

Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više